Introduction
The Aurora kinases constitute a family of serine/ threonine kinases that are essential for mitotic progression and maximally expressed during the G 2 and M phases of the cell cycle (Nigg, 2001; Carmena and Earnshaw, 2003) . There are three types of mammalian aurora kinases genes: Aurora-A, -B and -C.
Aurora-A localizes to centrosomes and is required for the separation and maturation of centrosomes through the recruitment of key components of spindle assembly. Depletion of Aurora-A by RNA interference blocks the G 2 -M transition (Hirota et al., 2003) . Aurora-A phosphorylates a series of prominent substrates, including BRCA1 (Ouchi et al., 2004) , CDC25B and p53 , and cells that overexpress Aurora-A are resistant to paclitaxel, bypass the radioinduced G 2 -M arrest (Anand et al., 2003) and exhibit decreased p53-dependent, cisplatin-induced apoptosis .
Aurora-B kinase is one of the chromosomal passenger proteins that are essential for mitotic progression. Aurora-B expression and activity are regulated by the cell cycle: its expression peaks at the G 2 -M transition, and its kinase activity is maximal during mitosis. Chromosomal passenger proteins localize to the kinetochores/centromeres from prophase to metaphase, at the central spindle in anaphase and telophase, and finally to the midbody at the end of cytokinesis. INCENP, also a substrate of Aurora-B, is required to localize Aurora-B to the kinetochores. Aurora-B activation is triggered by autophosphorylation after association with its substrate INCENP. In mammalian cells, Aurora-B forms a large chromosome passenger complex with INCENP, Survivin and Borealin (Adams et al., 2001; Carmena and Earnshaw, 2003; Meraldi et al., 2004; Andrews, 2005) .
In addition to its essential contribution to cytokinesis (Giet et al., 2005) , Aurora-B fulfills at least two additional, distinct yet related functions: Aurora-B phosphorylates histone H3 on Ser 10 (is required for the condensation of chromosomes) and is required for the tension-sensing spindle-assembly checkpoint and the correction of errors in the attachment of microtubules to kinetochores. Loss of Aurora-B function results in failure to retain checkpoint proteins at the kinetochore and an override of the Taxol-sensitive, tension-sensing spindle checkpoint (Ditchfield et al., 2003; Hauf et al., 2003) .
The identification of Aurora-B inhibitors has been a major target of pharmaceutical companies since the discovery that the corresponding gene locus is frequently amplified in human cancers and that Aurora-B is overexpressed at the mRNA and protein level in several human cancer cell lines (Bischoff et al., 1998) , including colon-rectum, breast and prostate cancer. Small molecules can selectively target the enzymatic activity of kinases by occupying the catalytic ATP (and sometimes the substrate)-binding site. Several Aurora kinase inhibitors have recently been described, including ZM447439 (Ditchfield et al., 2003; Gadea and Ruderman, 2005) , Hesperadin (Hauf et al., 2003) VX-680 (Harrington et al., 2004) and AZD1152 (Wilkinson et al., 2007) .
AZD1152 is an acetanilide-substituted pyrazoleaminoquinazoline dihydrogen phosphate prodrug with good solubility, making it suitable for parental administration. AZD1152 is a specific Aurora kinase inhibitor with selectivity for Aurora-B kinase (Ki 0.4 nM), and displays strong specificity over a panel of 50 additional serine-threonine and tyrosine kinases tested. Treatment of human tumor cell lines with AZD1152-HQPA (the active drug in human plasma) in vitro leads to the suppression of the phosphorylation of histone H3 on serine 10. AZD1152-HQPA displays a novel mechanism of action by affecting chromosome alignment and segregation, causing cells to fail to divide, become polyploid and finally undergo apoptosis. AZD1152-HQPA is active across a variety of tumor cell lines, including MCF7, Colo205, HCT116, SW620, HeLa, and A549, with an inhibition of colony formation (IC 50 ) of 20-30 nM for inhibition of histone H3 phosphorylation (Wilkinson et al., 2007) .
Combining drugs with radiation is a common practice in cancer treatment, and aimed at achieving greater therapeutic effects than with single-modality therapy. Taxanes, which block cells in mitosis by increasing microtubule stabilization, have previously been shown to modify radiosensitivity in a time-and cell cycledependent manner (Milas et al., 1999) . This finding prompted us to evaluate the impact of AZD1152-induced inhibition of Aurora-B kinase on the radiosensitivity of tumor cells in vitro and in vivo.
Results
Decreased clonogenic survival in tumor cells pretreated with AZD1152-HQPA We first assayed the physiological consequences of AZD1152 inhibition of Aurora-B kinase activity by analysing the phosphorylation status of the quintessential Aurora-B substrate, histone H3. Incubation of HCT116 colon tumor cells with AZD1152-HQPA for 24 h led to the complete inhibition of histone H3 phosphorylation and we observed different spindle morphology with multiple spindle pole in the AZD1152-HQPA-treated cells as compared to control cells (Figure 1a) . Correspondingly, and consistent with previous reports, cell cycle analyses revealed that AZD1152-HQPA-treated cells progressively accumulated a DNA content greater than 4 N, indicating polyploidization due to mitotic failure ( Figure 1a) . Moreover, a large number of micronuclei and multinucleate cells have been detected in the cells exposed to AZD1152-HQPA in the HCT116 cell lines (Figure 1a) . This suggests the mitotic catastrophe rather than apoptosis (approximately 10% sub-G 1 as in Figure 1a ) predominate in AZD1152-related cell death. Clonogenic survival assays further revealed that AZD1152-HQPA effectively inhibited colony formation in the range of 10 nM to 1 mM, with IC 50 for the cell lines p53 À/À HCT116, HT29 and A549: 20.12, 150 and 20.16 nM, respectively (Figure 1c) , and enhanced cell death when administered 24 h prior to ionizing radiation (IR) treatment in the various cell lines (Figures 3a, c and 5) . We further explored the influence of Aurora-B inhibition by AZD1152-HQPA on BubR1 localization to kinetochores, and observed a diminution of BubR1 localization to kinetochores (an anti-kinetochore CREST antibody has been used to mark the kinetochores that has not been changed by inhibition of Aurora-B by AZD1152) in the p53 À/À HCT116 cells with 24 h exposure of 100 nM AZD1152-HQPA (Figure 1d ).
Cell cycle response to IR and AZD1152-HQPA treatment Cell cycle analysis revealed that AZD1152-HQPA treatment for 24 h had a major impact on the cell cycle of several cancer cell lines differing in their p53 status (p53 À/À HCT116, p53 wt HCT116 (Figures 2a and b ) and HT29 cell lines; data not shown). The most prominent change induced by monotherapy with AZD1152-HQPA was an accumulation of cells with >4 N DNA content. Twenty-four hours after the treatment with IR, a more pronounced G 2 -M block was observed in p53 À/À HCT116 cells than in wild-type (wt) HCT116 cells (59 ± 7 versus 27 ± 5%, respectively), and AZD1152-HQPA was more efficient in inducing polyploidization in p53 À/À HCT116 cells than in p53 wt HCT116 counterparts (63 ± 12 versus 51 ± 15%, respectively). Notably, when cells were exposed to both IR and AZD1152-HQPA, the accumulation of >4 N DNA-content cells was reduced compared to treatment with AZD1152-HQPA alone in both cell lines wt HCT116: 18±1 versus 51±15%; p53 À/À HCT116: 25±12 versus 63±12%, respectively; Figures 2a and b) . However, when cells previously incubated with AZD1152-HQPA for 24 h were exposed to IR and analysed by fluorescenceactivated cell sorting (FACS) 24 h later, the accumulation of cells with >4 N DNA-content cells did not change when compared to cells exposed to AZD1152-HQPA alone. This phenomenon was observed in p53 À/À HCT116 as well as in their p53 wt HCT116 counterparts (data not shown).
We then compared the p21 Cip/WAF1 expression in the p53 wt and p53 À/À HCT116 (24 h after 100 nM AZD1152 HQPA). In Figure 2c , we show an increase of p21 Cip/WAF1 expression in AZD1152-exposed p53 wt HCT116 cells compared with dimethylsulfoxide (DMSO)-exposed control In vivo treatment of xenografted human cancer by the combination of AZD1152 plus IR Treatment of mice bearing subcutaneous p53 wt HCT116 cell xenografts revealed an increase in the tumor growth delay (TGD) induced by AZD1152 plus IR as compared with IR alone (16 days to reach a mean tumor volume of 800 mm 3 in controls compared to IR alone (26 days)), AZD1152 alone (22 days) and IR and AZD1152 (30 days); Figure 4b ). p53 À/À HCT116 tumors treated with AZD1152 plus IR also exhibited a more pronounced TGD (40 days) than tumors treated with IR alone (29 days; Figure 4c ). Figure 4a summarizes the in vivo TGDs obtained for p53 wt versus p53 À/À HCT116 after exposure to IR alone (10 and 8 days, respectively) and in combination with AZD1152 (15 and 19 days, respectively). Thus, AZD1152 has a particularly pronounced effect on the radiation response of p53-deficient tumors in vivo, consistent with the p53 dependency observed in vitro. The p53-mutated HT29 cell line yielded similar in vivo results ( Figure 4d ). Again, AZD1152 alone had a limited effect on the growth of HT29 tumors (27 days to reach a mean tumor volume of 800 mm 3 for AZD1152-treated cells compared to 25 days for control), whereas AZD1152 combined with IR led to a significant TGD (52 days for IR plus AZD1152 compared to 43 days for IR alone), as shown in Figure 4d .
Influence of depletion of Aurora-B on radiation response
In order to assess the contribution of Aurora-B to the radiosensitizing effect observed with AZD1152 treatment, we knocked down Aurora-B by means of two distinct short interference RNA (siRNA) heteroduplexes ( Figure 5a ). As expected, the depletion of Aurora-B could enhance the IR response of both p53 wt ( Figure 5b ) and p53
À/À (Figure 5c ) cells. To further elucidate the physiological contribution and potential mechanism of Aurora-B, we employed a tetracycline-inducible kinase-dead; Aurora-B (DN) mutant stably transfected into HEK293 cells (Girdler et al., 2006) . Expression of DN Aurora-B reduced phosphorylation of histone H3 (Girdler et al., 2006) , induced polyploidy ( Figure 6a ) and compromised clonogenic Enhanced radiation response in p53-deficient cells Y Tao et al survival (Girdler et al., 2006) . Similar to the results obtained with Aurora-B siRNA-transfected cells, we observed an enhancement of the radiation response in the HEK293 cells after tetracycline induction of DN Aurora-B (Figure 6b ) as compared to cells cultured in the absence of tetracycline or wt HEK293 cells (Figure 6c ). Pifithrin exposure did not affect the irradiation response with either wt or kinase-dead Aurora-B expression. Depletion or inhibition of Aurora-B can increase the radiation response, however, AZD1152 mediates additional radiosensitizing potential.
Cell cycle-dependent effect of AZD1152-HQPA-mediated radiosensitization To determine a putative cell cycle specificity of the AZD1152-HQPA-mediated radiosensitization, we selected HT29 cells in either the G 2 /M or G 1 /S phase of the cell cycle, and treated them with AZD1152-HQPA and/or IR. Cells enriched in the G 2 /M phase were well radiosensitized by AZD1152-HQPA (Figure 7b ). This radiosensitizing effect of AZD1152-HQPA was less pronounced when assessed on the population enriched in the G 1 /S phase, suggesting that radiosensitization mediated by AZD1152 is cell cycle dependent (Figure 7c ).
Absence of radiosensitization by AZD1152 in CHK2 and 14-3-3 s-deficient cell lines To determine whether other G 2 /M check point proteins than Aurora-B might be involved in AZD1152-mediated radiosensitization, we comparatively assessed the response of wt, CHK2 À/À and 14-3-3 s À/À HCT116 cells to IR and/or AZD1152-HQPA. Strikingly, we found that the knockout of CHK2 or 14-3-3 completely abolished the radiosensitizing effect of AZD1152-HQPA (Figure 8 ).
Discussion
In this study, we analysed the potential effects of AZD1152 in inhibiting Aurora-B kinase in conjugation AZD1152 is a radiosensitizer in vitro and in vivo Several Aurora kinase inhibitors (Keen and Taylor, 2004) , including ZM447439 (Ditchfield et al., 2003) , Hesperadin and VX-680 and AZD1152, have recently been described. Here, we describe that AZD1152-HQPA was able to inhibit colony formation in a dosedependent manner in several human cancer cell lines. We have previously reported that IR can give rise to the formation of micronucleated cells and subsequent mitotic catastrophe (Zhang et al., 2006) , raising the possibility that IR combined with inhibition of cell cycle checkpoints (that normally avoid mitotic catastrophe; Castedo et al., 2004) would be particularly efficient in inducing tumor cell death. Recently, another study (Tao et al., 2005) showed that activation of the spindle checkpoint followed by mitotic slippage initiates apoptosis, facilitated by KSP (kinesin-5, a mitotic spindle motor protein) inhibition. AZD1152-induced inhibition of Aurora-B could potentially override the spindle checkpoint and likely facilitate radiation-induced cell death. (Ditchfield et al., 2003) . It is likely that in the absence of p53, cells continued to cycle through aberrant mitoses, which ultimately resulted in cell death. Consistent with Enhanced radiation response in p53-deficient cells Y Tao et al this scenario, clonogenic survival assays showed that AZD1152 treatment led to enhanced cell death upon IR treatment in the presence of nonfunctional p53. Similarly, the extent of the in vivo effect was more potent with p53 À/À or p53 mutant cells. In HT29 cells, the extent of the TGD in animals treated with AZD1152 and IR group, compared to the moderate TGD in mice treated with AZD1152 alone suggests a synergistic interaction. In vivo results obtained with the HCT116 colon carcinoma confirmed that p53-deficient cells (as compared to p53 sufficient cells) exhibited a more pronounced TGD conferred by AZD1152 treatment, underscoring the impact of p53 on the system. This observation suggests that this Aurora-B inhibitor may exert an interestingly differential effect on normal versus tumor cells. Tumor cells in which the p53 system is frequently inactivated are particularly sensitive to the radiosensitizing effect of AZD1152, perhaps due to the absence of a radioprotective p53-dependent cell cycle checkpoint that backs up the spindle checkpoint system to prevent the propagation of cells carrying abnormal genomes (Keen and Taylor, 2004) . Hence, failure of the spindle assemble checkpoint (as a consequence of AZD1152 treatment) and the G 1 arrest after abnormal mitosis (as a consequence of p53 defects) would be particularly lethal after DNA damage by IR (Zhou and Bartek, 2004) .
Genetic inhibition of Aurora-B displays additive effects with irradiation but does not yield further synergy in p53-deficient cells In this study, genetic inhibition of Aurora-B using siRNAs or a conditional tetracycline-inducible DN Aurora-B mutant had radiosensitizing effects on several cell lines. However, no further synergy of radiation and Aurora-B inhibition was observed in cells lacking functional p53. We did observe a discrepancy between AZD1152 treatment and genetic inhibition of Aurora-B by siRNAs or expression of the DN mutant. Although AZD1152 and genetic Aurora-B inhibition had similar effects on cell cycle (polyploidy) and clonogenic survival (in the absence of IR), genetic Aurora-B inhibition failed to recapitulate the enhanced radiosensitization observed in p53-deficient cells. We could also show that AZD1152-mediated further radiosensitization in cells in which Aurora-B was inhibited by a DN mutant. Moreover, the fact that AZD1152 mediates further decrease in clonogenic survival in cells in which Aurora-B was inhibited also illustrates differences between genetic and pharmacological approaches against Aurora-B. The integrity of the p53-p21
Cip/WAF1 -dependent postmitotic checkpoint governs the response to Aurora kinases inhibition. It was recently shown that endoreduplication and apoptosis in response to VX-680 are limited in p53 wt cells and markedly enhanced in cells lacking p53. The difference in response to VX-680 among these cell lines correlates with the timing of induction of p21
Cip/WAF1 and its ability to inhibit cyclin E-cdk2 activity (Gizatullin et al., 2006) . We also show an increase of p21
Cip/WAF1 expression in AZD1152-exposed p53 wt HCT116 cells compared with DMSOexposed control cells, while there is little p21 Cip/WAF1 expression in p53 À/À HCT116 cells. These suggest the interplay between p53, its downstream effector p21
Cip/WAF1 and Aurora kinases. Altogether, this findings could reflect marked differences in terms of duration and intensity of Aurora-B inhibition between the genetic and the pharmacological approach, but one cannot rule out the fact that AZD1152 exerts an off-target effect on other cellular targets than Aurora-B.
Cell cycle (G 2 -M)-dependent effect of AZD1152 on irradiation In the G 2 /M phase, cells were more sensitive to the combined treatment with AZD1152 plus IR than when they were in the G 1 or S phases of the cell cycle. Tumors with defective checkpoints such as those with mutant p53 tended to selectively accumulate in G 2 after DNA damage. The G 2 /M checkpoint prevents cells from initiating mitosis when they sustain DNA damage during G 2 , or when they progress into G 2 with unrepaired damage inflicted during the previous S or G 1 phases (Kastan and Bartek, 2004) . p53-independent G 2 cell cycle checkpoints (Kastan and Bartek, 2004) arrest cells at the G 2 /M boundary after DNA damage by IR or other DNA-damaging agents. That the G 2 /M cell subpopulation exhibits higher sensitivity to IR when combined with AZD1152 has promising therapeutically implications, especially if combined with fractionated radiotherapy, which causes cells to accumulate in the G 2 /M boundary (Pawlik and Keyomarsi, 2004) .
The absence of radiosensitization by AZD1152 or ZM447439 in CHK2 À/À or 14-3-3 s À/À cells suggests that a normal G 2 -M checkpoint (which depends on the presence of CHK2 and 14-3-3 s) is critical for the therapeutic effect of AZD1152.
In conclusion, this study reveals that sequential treatment with AZD1152 and IR enhances cell death in HCT116, HT29 and A549 cancers. This effect was more pronounced in the absence of functional p53 and in G 2 /M-enriched cells. Preclinical data obtained in mice bearing human cancer xenografts strongly suggest that the radiosensitizing effect of AZD1152 warrants further clinical exploration.
Materials and methods

Cell lines
HCT116 human colorectal cancer cell lines (p53 wt , p53
À/À and 14-3-3 s À/À ) were a kind gift from B Vogelstein (Bunz et al., 1998; Chan et al., 1999; Jallepalli et al., 2003) . The HT29 colorectal cancer cell line (p53-and Raf-mutated), and A549 human non-small cell lung cancer cells (which carries an intact p53 pathway) were obtained from the American Type Culture Collection (Manassas, VA, USA). HCT116 and HT29 cells were maintained in McCoy's 5A medium (Gibco, Worcester, MA, USA) supplemented with 10% fetal bovine serum (ATGC, Cergy Pontoise, France), 1% PS (Gibco), 1% L-glutamine (Eurobio, Les Ulis, France), 1 mM sodium pyruvate (Gibco) and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic N) ) under tetracycline control were generated using the FRT-Flp-based system as previously described (Girdler et al., 2006) . Briefly, open reading frames were cloned into a pcDNA5-FRT-TO vector (Invitrogen, Carlsbad, CA, USA) modified to contain an N-terminal Myc-epitope tag. Resulting vectors were co-transfected into Flp-In TRex-HEK293 cells with pOG44, a plasmid encoding the Flp recombinase. After selection in hygromycin, colonies were pooled, expanded and transgene expression was induced with 0.25-1 mg ml À1 tetracycline. Cell culture conditions were carried out as described (Girdler et al., 2006) .
Clonogenic survival assays
Cells were seeded in triplicate in six-well plates or a 25 cm 2 flask in a range of 100-80 000 cells per well according to the radiation dose delivered to the cells, experimental conditions and the different cell lines, in order to yield 20-200 colonies per flask or well. Once cells were attached, a single dose of photon irradiation with/without drug was delivered. Cells were cultured in a 37 1C, 5% CO 2 incubator for 10-14 days. Individual colonies (>50 cells per colony) were fixed and stained for 20 min with a solution containing crystal violet and methanol. The plating efficiency (PE) corresponds to the percentage of seeded cells that grow into colonies under the specific culture conditions of a given cell line. PE AZD is the percentage of seeded cells that grow into colonies when exposed to AZD1152-HQPA for a given cell line. PE DMSO is the percentage of seeded cells that grow into colonies when exposed to DMSO (used as a control) for a given cell line. We calculated the ratio of PE AZD /PE DMSO as an estimate of the percentage of cell killing in certain cell lines caused by AZD1152-HQPA alone using a colony-formation method. The survival fraction, expressed as a function of irradiation, was calculated as follows: survival fraction ¼ colonies counted/ (seeded cells Â PE/100). A 200 kV X-ray device (0.66 Gy min Aurora-B kinase inhibitors AZD1152 (provided by AstraZeneca Pharmaceuticals, Macclesfield, UK) is an Aurora kinase inhibitor with selectivity for Aurora-B. AZD1152 is a phosphate prodrug that is converted in vivo into the active agent AZD1152-HQPA (diluted in DMSO at a concentration of 10 mM). AZD1152-HQPA (Ki: Aurora-A 1370 nM, Aurora-B-INCENP 0.36 nM, Aurora-C-INCENP 17 nM, relative molecular mass 507.57) was used in vitro. Screening of a kinase panel indicated that, testing at doses of up to 100 times higher than those required to inhibit Aurora-B, AZD1152-HQPA did not significantly inhibit any of the following 27 kinases: JAK3, v-ABL, IGFR, ZAP70, P38, CDK1, CDK2, JNK1A, PKA, MEK, MTK, TEK, TRK, EGFR, ErbB2, P70, PLK, PDGFRa, PDGFRb, PI3K, KIS, KDR, FLT1, FLT3, FGFR, C-KIT and B-sRAF. The duration of cell incubation with AZD1152 in vitro was 24 h, if not specified otherwise. ZM447439 (provided by AstraZeneca Pharmaceuticals) is an Aurora kinase inhibitor. In in vitro kinase assays using purified recombinant proteins, ZM447439 inhibited Aurora-A and -B with IC 50 values of 1000 and 50 nM, respectively (Girdler et al., 2006) .
siRNA The following siRNAs were followed for analyses: two human Aurora-B (QIAGEN, Hilden, Germany), GGAG GAGGAUCUACUUGAU; AURKB 2 (HP Genomewide siRNA 1027400) and AURKB 5 (HP-validated siRNA 1027400). The first siRNA AURKB 2 has been successfully confirmed in previous siRNA experiments. siRNA transfections were conducted with Oligofectamine transfection reagent (Invitrogen), and a nonspecific double-stranded RNA (QIAGEN) was used as a control. Annealing of the component siRNA strands and transfection procedures were performed as previously described (Elbashir et al., 2001) .
The p53 inhibitor Pifithrin-a (Komarov et al., 1999) was used for p53 inhibition in A549 cells. The final concentration used in experiments was 10-20 mM in medium with serum. Pifithrin-a was added 8 h prior to AZD1152 treatment.
Cell cycle analysis
Sham control and 6 Gy-irradiated cells with/without drug exposure were harvested by trypsinization at the indicated time after irradiation, washed with ice-cold PBS, fixed in 70% ethanol and stored at À20 1C. Prior to DNA analysis, DNA content was labeled with 0.1 mg ml À1 propidium iodide (PI) and 1 mg ml À1 RNAse. The cell cycle analysis was performed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA).
Purification of selected cell cycle subpopulations
Twenty-four hours after incubation with AZD1152-HQPA, HT29 cells were trypsinized, neutralized with medium, centrifuged and then stained with 10 mg ml À1 of Hoechst 33342 (Molecular Probes, Eugene, USA) for 30 min at 37 1C in the absence of light. Samples were washed once and resuspended in medium containing 0.5 mg ml À1 PI. Selection of G 2 -M and G 1 -S phase cells was performed using a FACS Vantage SE (BD Biosciences).
Immuno(cyto)chemistry and antibodies HCT116 cells were seeded in 12-well plates, incubated with 100 nM AZD1152-HQPA for 1 or 24 h and fixed in 4% paraformaldehyde (Sigma) for 30 min. Cells were then permeabilized with PBS containing 0.1% Triton X-100 for 3 min and incubated with 1 mg ml À1 BSA/PBS blocking solution. Cells were incubated with phospho-histone-H3 PhH3 (1:500, catalog no. 06-570; Upstate Cell Signaling Solutions, Danvers, MA, USA) and mouse monoclonal antib-tubulin (1:200, catalog no. ATN01-A; Cytoskeleton, Denver, CO, USA) primary antibodies, followed by incubation with goat anti-rabbit immunoglobulin G (IgG) conjugated to Alexa 555 fluorochrome (Molecular Probes, Eugene, OR, USA) or anti-mouse IgG Alexa 488 conjugate (1:500, Molecular Probes) secondary antibodies. The mouse monoclonal antiBubR1 (1:100, catalog no. B34920; BD Transduction Laboratories) antibody had been used and a human anti-kinetochore antibody (1:200, obtained from patients with calcinosis cutis, Raynaud phenomenon, esophageal motility disorder, sclerodactyly and telangiectasis (CREST) syndrome) was kindly provided by JC Brouet, Hopital St Louis, Paris, France. The p21
Cip/WAF1 antibody (1:500; catalog no. 05-345, Upstate) has been used to detect p21
Cip/WAF1 expression 24 h after 100 nM
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